Insilico Medicine used artificial intelligence to develop rentosertib, a drug for chronic lung disease, and early trial data suggests it may also reduce biological markers of aging. The findings come with major caveats: the sample size was small, the drug hasn't been tested in healthy people, and the "aging clocks" used to measure results are scientifically debated.

• Rentosertib reduced biological aging markers across six different AI-based "aging clocks" in a clinical trial, according to results published in Nature Biotechnology.
• The drug was originally developed for idiopathic pulmonary fibrosis (IPF) and has only been tested in sick patients, not healthy ones, so anti-aging claims remain speculative.
• The study has significant limitations: small sample size, unproven reliability of aging clock measurements, and the drug is still years away from regulatory approval even for its primary lung disease indication.